Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» CSL
CSL
Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte
Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte
Endpoints
CSL
MRNA
Pharma CEOs
Paul McKenzie
Flag link:
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Drugs.com
CSL
clinical trials
garadacimab
HAE
Flag link:
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
BioSpace
CSL
Europe
Hemgenix
gene therapy
hemophilia B
Flag link:
Big pharma’s new year catalysts
Big pharma’s new year catalysts
EP Vantage
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Flag link:
Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small
Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small
Forbes
Hemgenix
gene therapy
hemophilia B
drug pricing
CSL
Flag link:
10 Massachusetts Biopharma Companies Hiring Now
10 Massachusetts Biopharma Companies Hiring Now
BioSpace
Massachusetts
hirings
AbbVie
Moderna Therapeutics
CSL
Intellia Therapeutics
Schrödinger
Visterra
Alloy Therapeutics
Werewolf Therapeutics
Sherlock Biosciences
Flag link:
A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount
A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount
Medical Marketing and Media
CSL
Hemgenix
drug pricing
hemophila B
Flag link:
uniQure, CSL claim first okay for hemophilia B gene therapy
uniQure, CSL claim first okay for hemophilia B gene therapy
Pharmaphorum
uniQure
CSL
hemophila B
gene therapy
Hemgenix
FDA
Flag link:
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
Flag link:
CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
Pharmaphorum
CSL
Arcturus
vaccines
MRNA
Flag link:
CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies
CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies
Endpoints
CSL
R&D
Germany
vaccines
gene therapy
cell therapy
Flag link:
CSL reports Phase III data for garadacimab to treat hereditary angioedema
CSL reports Phase III data for garadacimab to treat hereditary angioedema
Clinical Trials Arena
CSL
clinical trials
garadacimab
HAE
hereditary angiodema
Flag link:
CSL Launches New Unified Global Brand Identity
CSL Launches New Unified Global Brand Identity
BioSpace
CSL
rebranding
Flag link:
After delay, CSL's $11.7B deal for Vifor poised to close next week
After delay, CSL's $11.7B deal for Vifor poised to close next week
Fierce Pharma
M&A
CSL
Vifor
antitrust
Flag link:
CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb
CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb
Endpoints
CSL
Seqirus
drug manufacturing
North Carolina
Flag link:
The top 10 biopharma M&A deals in 2021
The top 10 biopharma M&A deals in 2021
Fierce Pharma
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Flag link:
Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing
Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing
Endpoints
Vifor Pharma
CSL
M&A
Flag link:
Biopharma’s buyout year ends with a bang
Biopharma’s buyout year ends with a bang
EP Vantage
M&A
CSL
Vifor Pharma
Pfizer
Arena Pharmaceuticals
Flag link:
As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report
As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report
Endpoints
M&A
Vifor Pharma
CSL
Flag link:
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Fierce Pharma
Takeda
CSL
hereditary angiodema
HAE
RWE
Takhzyro
Cinryze
Haegarda
Flag link:
Pages
1
2
3
4
next ›
last »